Study of apatinib plus chemotherapy for recurrent childhood medulloblastoma
Part of Cancer clinical trials.
This trial tests whether adding apatinib to temozolomide and etoposide helps children whose medulloblastoma has come back. It aims to slow the tumor and improve outcomes after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 2 to 21 at diagnosis, and have medulloblastoma confirmed by biopsy or surgery
- Have confirmed tumor recurrence on MRI (at least a 1 cm enhancing lesion seen across at least 2 slices)
- Finish prior radiation at least 4 weeks ago, and prior chemotherapy at least 4 weeks ago (and fully recovered
- Have enough strength/ability for treatment (KPS ≥50 if over 12, or Lansky ≥50 if 12 or younger)
- Have generally normal heart, lungs, liver, kidneys, blood counts, and clotting tests, with no active serious problems
- Be able to swallow capsules and agree to provide tumor tissue samples for the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether apatinib can shrink or control recurring atypical/malignant meningioma that has come back after surgery and radiation. It focuses on adults with measurable regrowth on MRI and good overall health to safely take an oral medicine.
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
This trial tests a combination of four drugs (chidamide, dinutuximab beta, irinotecan, and temozolomide) for children whose neuroblastoma has returned or isn't responding to standard treatment. It aims to see if this mix can shrink the tumor or stop it from growing.
This trial studies whether apatinib, a targeted medicine, combined with an immunotherapy treatment can shrink or control neuroblastoma that has come back or does not respond to prior treatment. Because it is a Phase I/II single-group study, everyone receives the planned treatment and researchers watch side effects and response.
This trial tests a combination of two oral drugs (axitinib and metronomic etoposide) for children and young adults whose medulloblastoma or ependymoma has come back or is not responding to standard therapy. The goal is to see if this daily pill treatment can control tumor growth with manageable side effects.
This trial tests a treatment that targets tumor blood-vessel growth to slow or shrink relapsed/progressive brain tumors in children. It may help if standard options are no longer working.
Hear when a new Recurrent Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.